Free Trial

19,790 Shares in The Chemours Company (NYSE:CC) Purchased by Proficio Capital Partners LLC

Chemours logo with Basic Materials background
Remove Ads

Proficio Capital Partners LLC bought a new stake in The Chemours Company (NYSE:CC - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 19,790 shares of the specialty chemicals company's stock, valued at approximately $334,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. State of New Jersey Common Pension Fund D increased its position in Chemours by 39.1% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 101,670 shares of the specialty chemicals company's stock worth $2,066,000 after purchasing an additional 28,591 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Chemours in the third quarter worth about $1,615,000. Victory Capital Management Inc. raised its stake in Chemours by 206.2% during the third quarter. Victory Capital Management Inc. now owns 103,259 shares of the specialty chemicals company's stock valued at $2,098,000 after buying an additional 69,531 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Chemours during the third quarter valued at approximately $285,000. Finally, KBC Group NV grew its holdings in Chemours by 19.5% in the 3rd quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company's stock worth $91,000 after buying an additional 728 shares in the last quarter. Hedge funds and other institutional investors own 76.26% of the company's stock.

Chemours Stock Up 1.8 %

Shares of NYSE CC opened at $13.69 on Wednesday. The business's 50 day moving average is $17.38 and its two-hundred day moving average is $18.59. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of 24.02 and a beta of 2.00. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The Chemours Company has a 52-week low of $13.09 and a 52-week high of $29.21.

Remove Ads

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.01. The firm had revenue of $1.36 billion during the quarter, compared to analysts' expectations of $1.37 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. Research analysts predict that The Chemours Company will post 2.03 EPS for the current year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 14th. Investors of record on Friday, February 28th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 7.30%. The ex-dividend date is Friday, February 28th. Chemours's dividend payout ratio is presently 175.44%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CC shares. Morgan Stanley lowered their price target on Chemours from $25.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Barclays lowered their target price on shares of Chemours from $23.00 to $19.00 and set an "equal weight" rating for the company in a report on Monday, February 24th. Mizuho cut their price objective on shares of Chemours from $22.00 to $21.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. Royal Bank of Canada restated an "outperform" rating and set a $25.00 price objective on shares of Chemours in a research note on Thursday, December 12th. Finally, Truist Financial assumed coverage on shares of Chemours in a research report on Tuesday, January 28th. They set a "buy" rating and a $27.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Chemours presently has a consensus rating of "Hold" and an average target price of $23.11.

Read Our Latest Report on Chemours

Chemours Company Profile

(Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Featured Stories

Institutional Ownership by Quarter for Chemours (NYSE:CC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Chemours Right Now?

Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Best ETFs for Spring 2025: Strong and Steady Investing
Is There Still Money in AI? How to Invest in the Next Big Wave
AMD at Rock Bottom? Analysts Predict a MAJOR Rebound!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads